Oxidative Capacity and Exercise Tolerance in Ambulatory SMA

Sponsor

Columbia University (Other)

Overall Status

Completed

CT.gov ID

NCT02895789

Collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH), Muscular Dystrophy Association (Other)

Enrollment

Location

Actual Duration (Months)

0.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This proposal will focus on (1) estimating oxidative capacity of specific muscle groups during exercise using near infrared spectroscopy and (2) describing body composition to better understand exercise capacity and mitochondrial function in ambulatory spinal muscular atrophy (SMA) patients and disease controls. It is a 6-month observational study including 14 ambulatory SMA patients, 14 ambulatory patients with mitochondrial myopathy, and 14 healthy controls.

Condition or Disease	Intervention/Treatment	Phase
Spinal Muscular Atrophy Type 3 Mitochondrial Myopathy

Detailed Description

Spinal Muscular Atrophy (SMA) is a progressive, recessively-inherited neuromuscular disease characterized by weakness and muscle atrophy due to the loss of spinal cord motor neurons. The results from this study would provide preliminary data, using non-invasive methods, on oxidative capacity in ambulatory SMA patients and disease controls to aid in the design of exercise intervention studies. Furthermore, this information would link previous laboratory and preclinical findings of mitochondrial depletion in SMA to the clinical condition and provide important information for future studies designed to improve oxidative capacity and fitness in SMA patients.

Study Design

Study Type:

Observational

Actual Enrollment :

42 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Evaluation of Oxidative Capacity and Exercise Tolerance in Ambulatory Patients With Spinal Muscular Atrophy (SMA)

Actual Study Start Date :

Nov 1, 2016

Actual Primary Completion Date :

Oct 1, 2020

Actual Study Completion Date :

Jan 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
spinal muscular atrophy ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with laboratory documentation of homozygous deletion of SMN1 exon 7
mitochondrial myopathy ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with genetic confirmation or evidence from muscle biopsy confirming the diagnosis
control The healthy control group will be age and gender-matched to the SMA and mitochondrial myopathy groups as best as possible.

Outcome Measures

Primary Outcome Measures

Change in NIRS derived index of muscle oxygen extraction [baseline, 6 months]
Near Infrared Spectroscopy (NIRS) is a simple, non-invasive method to measure oxygen in muscle and other tissues in vivo.

Secondary Outcome Measures

Change in Peak oxygen uptake (V02 max) [baseline, 6 months]
Participants will undergo an exercise stress test performed by a clinical exercise physiologist using an electronically-braked recumbent cycle ergometer to determine peak oxygen uptake (VO2 max).
Change in Distance walked during the Six Minute Walk Test (6MWT) [baseline, 6 months]
6MWT is an objective evaluation of functional exercise capacity, measures the maximum distance a person can walk in six minutes over a 25-meter linear course.
Change in Lean body mass assessed with Dual Energy X-ray Absorptiometry (DEXA) [baseline, 6 months]
Dual-Energy X-ray Absorptiometry (DEXA) is a method of estimating bone and lean body mass by comparing the absorption of two distinct energy level beams at 46.8 keV and 80 keV, which are effective at differentiating soft tissue and bone. A standard DEXA scan will be performed in supine.

Eligibility Criteria

Criteria

Ages Eligible for Study:

8 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

One of the following categories:

Genetic confirmation of SMA with laboratory documentation of homozygous deletion of SMN1 exon 7;
Genetic confirmation of mitochondrial myopathy or evidence from muscle biopsy confirming the diagnosis; or
Healthy individuals.

Able to walk independently at least 25 meters, and able to tread a stationary cycle ergometer.

Exclusion Criteria:

Unable to walk 25 meters independently.
Use of investigational medications intended for the treatment of SMA within 30 days prior to study entry.
The presence of any contraindication to exercise according the ACSM criteria.

Patients with and without Spinraza treatment are eligible.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Columbia University Medical Center	New York	New York	United States	10032

Sponsors and Collaborators

Columbia University
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Muscular Dystrophy Association

Investigators

Principal Investigator: Jacqueline Montes, PT, EdD, Columbia University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Jacqueline Montes, Assistant Professor of Rehabilitation and Regenerative Medicine , Rehab & Regenerative Med PT, Columbia University

ClinicalTrials.gov Identifier:

NCT02895789

Other Study ID Numbers:

AAAQ9447
1K01HD084690-01A1

First Posted:

Sep 12, 2016

Last Update Posted:

Mar 8, 2022

Last Verified:

Mar 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD:

Undecided

Keywords provided by Jacqueline Montes, Assistant Professor of Rehabilitation and Regenerative Medicine , Rehab & Regenerative Med PT, Columbia University

spinal muscular atrophy

oxidative capacity

exercise tolerance

mitochondrial myopathy

SMA

six minute walk test

neuromuscular disease

near infrared spectroscopy